Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed...Line Sale Agreement • October 3rd, 2014 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New Jersey
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 11th day of August, 2014 (“Effective Date”), by and between Trillium Therapeutics Inc., an Ontario corporation, with a place of business at 96 Skyway Avenue, Toronto, Ontario M9W, 4Y9, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
CONFIDENTIAL GPEx®-DERIVED CELL LINE SALE AGREEMENTLine Sale Agreement • July 9th, 2018 • Vaccinex, Inc. • Pharmaceutical preparations • New York
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 13th day of January, 2010 (“Effective Date”), by and between Vaccinex, Inc., a Delaware corporation, with a place of business at 1895 Mt. Hope Avenue, Rochester, NY, 14620 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
GPEx®-DERIVED CELL LINE SALE AGREEMENTLine Sale Agreement • November 1st, 2018 • DiaMedica Therapeutics Inc. • Pharmaceutical preparations • New York
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 2nd day of February, 2012 (“Effective Date”), by and between DiaMedica Inc., a Manitoba corporation, with a place of business at 200 – 135 Innovation Drive, Winnipeg, Manitoba, R3T 6A8, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
GPEx® CELL LINE SALE AGREEMENTLine Sale Agreement • August 11th, 2014 • EPIRUS Biopharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey
This GPEx® Cell Line Sale Agreement (“Agreement”) is made and is effective as of this 1st day of January, 2009 (the “Effective Date”), by and between Catalent Pharma Solutions, LLC, a Delaware limited liability company, having a place of business at 8137 Forsythia Street, Middleton, Wisconsin 53562 USA (“Catalent”), and Moksha8 Pharmaceuticals, Inc., a Delaware corporation, having a place of business at 1550 Liberty Ridge Drive, Wayne, PA 19087, USA (“Moksha8”).
